Clinical Applications of Aldosterone In Vivo Secretion Rate

  • Bernard Kliman


Several investigators have described procedures for the indirect measurement of the aldosterone secretion rate in man [1–5]. The general method is dependent on intravenous administration of a dose of radioactive aldosterone, the resultant in vivo dilution of the tracer by endogenous steroid, and measurement of this dilution by isolation of a specific metabolite fraction from the urine excreted during a measured time interval. The process of dilution is influenced by the presence of a body pool of steroid at the beginning and end of the study. The apparent secretion rate is therefore more representative of the amount of steroid removed rather than that secreted during the chosen time period. Despite these and other factors, the method has become useful as an approximation of secretion rate. The methods in current use differ mainly in the metabolite fraction chosen, the purification method, and the means of measurement of total steroid in the isolated sample. This discussion will be based on the method of Peterson [2]


Congenital Adrenal Hyperplasia Secretion Rate Acetic Anhydride Urinary Tract Obstruction Endogenous Steroid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Click, S., Laragh, J. H., and Lieberman, S., Trans. Assoc. Am. Physicians 71: 225 (1958).Google Scholar
  2. 2.
    Peterson, R. E., Recent Progr. Hormone Res. 15: 231 (1959).Google Scholar
  3. 3.
    Flood, C., Layne, D. S., Ramcharan, S., Rossipal, E., Tait, J. F., and Tait, S. A. S., Acta Endocr. 36: 237 (1961).Google Scholar
  4. 4.
    Siegenthaler, W. E., Dowdy, A., and Luetscher, J. A., J. Clin. Endo. Metab. 22: 172 (1962).CrossRefGoogle Scholar
  5. 5.
    Cope, C. L., Harwood, M., and Pearson, J„ Brit. Med. J. 1: 659 (1962).CrossRefGoogle Scholar
  6. 6.
    Bush, I.E., Biochem, J. 50, 370 (1952).Google Scholar
  7. 7.
    Kliman, B., and Peterson, R. E., J. Biol. Chem. 235: 1639 (1960).Google Scholar
  8. 8.
    Christy, N.P., and Laragh, J. H., New Engl. J. Med. 265: 1083 (1961).CrossRefGoogle Scholar
  9. 9.
    Kliman, B., Rahill, J., and Bartter, F. C., Endocrine Soc. Meetg., New York City, June, 1961.Google Scholar
  10. 10.
    Kliman, B., Bell, N., and Bartter, F. C., Clin. Res. 9: 182 (1961).Google Scholar
  11. 11.
    Bryan, G. T., Kliman, B., and Bartter, F.C., Clin. Res. 10: 223 (1962).Google Scholar
  12. 12.
    Bryan, G. T., Kliman, B., Gill, J. R., Jr., and Bartter, F. C., J. Clin. Endo. Metab. 24: 729 (1964).CrossRefGoogle Scholar

Copyright information

© New England Nuclear Corporation 1965

Authors and Affiliations

  • Bernard Kliman
    • 1
  1. 1.Harvard Medical SchoolBostonUSA

Personalised recommendations